< 1 minute read
Nov. 3, 2021

An Oral BMS HPK1 Inhibitor Tool Compound from Homology Modeling

BMS compound 24 - HPK1

50x family-selective HPK1 kinase inhibitor tumor clearance w/ PD-1i (oral 100 mpk BID) from IRAK4 inhibitor and homology modeling ACS. Med. Chem. Lett., Feb. 19, 2021 Bristol Myers Squibb, Cambridge, MA

Drug Hunter Team

The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The starting point was an IRAK4 kinase inhibitor identified from historical kinome selectivity data. A homology-model based on MST1 was used for [...]



Other molecules you may be interested in